Genomic Testing for Prenatal Clinical Evaluation of Congenital Anomalies by Rudolf, Gorazd et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 19
Genomic Testing for Prenatal Clinical Evaluation of
Congenital Anomalies
Gorazd Rudolf, Luca Lovrečić, Aleš Maver,
Marija Volk and Borut Peterlin
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.73247
Abstract
Congenital anomalies occur in about 2–3% of liveborn and 20% of stillborn infants. They
constitute a serious public health and epidemiological problem. The etiology of congenital
anomalies is complex; they can result from genetic factors, environmental factors, or a
combination of both. It is estimated that genetic factors represent an important cause of
congenital anomalies and may be due to different genetic mechanisms: aneuploidies,
deletions and duplications of DNA segments, and single gene disorders. Due to the
genetic complexity, the targeted prenatal genetic diagnostics of congenital anomalies is
usually problematic and challenging. In recent years new diagnostic algorithms for pre-
natal genetic testing are being developed with the advent of new genomic technologies,
like molecular karyotyping and next-generation sequencing. These technologies offer
testing options that exceed conventional karyotyping and targeted molecular genetic
testing with better diagnostic yield. In this chapter, an overview of the conventional
genetic diagnostic approach and the use of new genomic technologies in the diagnostic
algorithm of prenatally detected congenital anomalies are discussed.
Keywords: congenital anomalies, epidemiology, etiology, conventional karyotyping,
molecular karyotyping, next-generation sequencing, prenatal diagnostics
1. Introduction
Congenital anomalies (CAs) occur in about 2–3% of liveborn and 20% of stillborn infants. They
are an important cause of neonatal mortality, children morbidity, and long-term disability and
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so constitute a serious public health and epidemiological problem [1]. A significant proportion
of CAs is detected before birth by routine ultrasound examination and other screening tech-
niques [2]. Prenatal identification of CAs can have significant emotional and psychological
consequences for parents and affected babies [2]. Therefore, it is imperative to make the right
diagnosis as soon and as accurate as possible. Genetic testing in prenatal period is an area with
very sensitive and ethically challenging situations [3]. Determining a genetic diagnosis prena-
tally permits parents to make informative reproductive decisions and to be counseled about
possible fetal outcomes [4]. It adds important information for current pregnancy in the terms
of full phenotype beyond ultrasonographically detected abnormalities on the one hand and
postnatal prognosis on the other [3]. Consequently, it is important to use appropriate genetic
testing approach to obtain a specific diagnosis.
In recent years new diagnostic algorithms for prenatal genetic testing are being developed
with the advent of new genomic technologies, like molecular karyotyping (comparative geno-
mic hybridization) and next-generation sequencing (NGS). These technologies offer testing
options that exceed conventional karyotyping of the fetus and provide better diagnostic yield.
Despite the evidence of important additional diagnostic yield of new technologies in the
etiology of CAs, they have not been systematically implemented in clinical prenatal diagnostic
algorithms in several national healthcare systems.
2. The epidemiology and etiology of CA
A CA is defined as any structural anomaly present at birth. Major CAs are anomalies that have
medical, surgical, or cosmetic significance and occur in about 2–3% of liveborn and 20% of
stillborn infants [1]. Thus, CAs are more prevalent that many chronic childhood diseases, such
as autism, pediatric cancers, and type 1 diabetes, are an important cause of neonatal mortality,
children morbidity, and long-term disability [1, 5]. Therefore, they represent an important
public health and epidemiological problem.
CAs can be isolated or present in a characteristic pattern affecting one or more organ systems.
The overall prevalence of most major CAs does not vary much across ethnic groups [6, 7].
However, the risk for different types of anomalies is variable and may be related to genetic
susceptibilities and also to cultural and social differences that can influence exposures (e.g.,
neural tube defects due to a dietary deficiency of folic acid) [6, 7]. The prevalence of most major
birth defects over time has remained constant, but some have shown a significant increase
such as gastroschisis [6, 7].
The etiology of CAs is complex. CAs can be the result of genetic factors, environmental factors,
or a combination of both [8, 9], although the underlying etiology often remains unknown. It is
estimated that genetic factors represent an important cause of CAs andmay result from different
genetic mechanisms: the most common are aneuploidies, deletions, and duplications of DNA
segments (collectively known as CNV), and single gene disorders [8, 9]. Some disorders have an
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epigenetic basis; genes can be silenced or activated by modifications that may depend on the
parent of origin or other influences [4].
With the traditional diagnostic approach using conventional karyotyping and direct molecular
genetic testing, the etiology of CAs remains undiagnosed in 65–70%, including cases with
multifactorial or polygenic etiology (e.g., isolated neural tube defects or cleft palate), 15–25%
is thought to be genetic or genomic—chromosomal in 10–15% and monogenic in 10%—and
10% is thought to be due to environmental factors [4]. Although most CAs are isolated and
sporadic; the genetic contribution has long been recognized, and specific genes involved are
increasingly being identified. However, the majority of isolated CAs are thought to be caused
by a complex interplay of genetic and environmental factors and follow the so-called multifac-
torial or polygenic inheritance [4, 8, 9]. On the other hand, multiple CAs are often part of a
syndrome, of chromosomal or monogenic etiology.
In the prenatal settings, the frequency of chromosomal abnormalities depends on many fac-
tors: the gestational age, type of the anomaly, the number of anomalies, and the combination of
anomalies identified [10]. In retrospective series, chromosomal abnormalities were found in
2–18% of cases when isolated and in 18–35% when multiple CAs were prenatally detected on
ultrasound [10, 11]. Chromosomal abnormalities are more common in spontaneous abortions
(50%) than in stillbirths (6–13%) [12].
Due to the frequency, morbidity and lethality CAs pose an important public healthcare prob-
lem. For the planning of preventive healthcare measures, it is very important to determine the
epidemiology and etiology of CAs.
The following chapters give an overview of the conventional genetic diagnostic approach and
the use of new genomic technologies in the prenatal genetic diagnosis of CAs.
3. Conventional genetic diagnostic approach
Currently fetal karyotyping and targeted genetic testing are still most commonly used in the
genetic diagnostic evaluation of high-risk pregnancies including morphologically abnormal
fetus detected by ultrasound examination and positive result of the screening test or due to
parental chromosome rearrangement or genetic disorder with a known pathogenic variant.
Despite the recent shift of genetic diagnostics toward genomic approach, the conventional
diagnostic approach encompassing the karyotyping and targeted molecular genetic testing is
worth noting.
3.1. Karyotyping
To identify possible genetic causes underlying ultrasonographically detected CAs or positive
result of the screening test (nuchal translucency, combined screening test, triple/quadruple
hormone test), a full chromosome analysis has been widely used and regarded as the gold
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standard from the late 1990s to about 2010. A diagnostic yield of classical karyotype is more
than 18% in fetuses presenting with isolated or multiple CAs [10].
As chromosome analysis is subjective and experience-dependent [13], its insufficiencies have
been complemented by fluorescent in situ hybridization (FISH) analysis, where a DNA-
specific fluorescent probe is hybridized to the complementary sequence in a cell preparation.
In contrast to conventional chromosome analysis, FISH can be used to study cultured or direct
cell preparations (metaphase/interphase FISH). FISH allows for the detection of repetitive
regions like satellites in the acrocentric chromosome or variable length of pericentromeric
heterochromatin not covered by genomic methods [13]. Currently, FISH analysis is a valuable
tool for the identification of the origin of the marker chromosome composed of heterochroma-
tin [14] and complex chromosome rearrangements and mechanism of the chromosome
rearrangement [15, 16]. Locus-specific fluorescent probes detect subtelomere and interstitial
submicroscopic chromosomal rearrangements associated with clinically recognizable pheno-
types with diagnostic yield of 3–6% for chromosome abnormalities [17]. However, screening
with FISH for tandem duplications seems to be of limited value.
FISH is a more targeted approach, because it requires prior knowledge of chromosome region
of interest but has limited utility as a first-tier investigation [18].
Chromosome analysis may also be considered as a quantitative method, which can accurately
detect the proportion of the mosaicism. As many as 0.16% of cases with low-level yet clinically
significant chromosome mosaicism would be undetected by array CGH method [18]. In addi-
tion, in mosaic cases with two abnormal cell lines resulting in a no-net gain or loss (i.e., 45,X/47,
XXX) array, CGH would return to normal result [18].
Different types of mosaicism can be found in prenatal diagnostics, like confined placental
mosaicism (CPM), true fetal mosaicism, and clonal expansion because of in vitro cultivation
[20]. CPM is found in about 1–2% of chorionic villi samples, and certain chromosome trisomies
are typically found, like trisomy of chromosome 2, 7, or 16 [19].
Over the last decades, chromosome analysis has been the cornerstone in prenatal genetic
diagnosis. In fetuses with multiple CA, there is a chance of more than 18% to detect a
chromosomal abnormality [11], while a chance for a chromosomal aberration in cases with an
isolated CA is not well determined [20, 21].
There are some pros to why fetal karyotyping remains in the everyday genetic practice. The
chromosome analysis assesses the number (aneuploidies) and the structure of chromosomes
(chromosome rearrangements) in a single assay (i.e., free trisomy 21 versus unbalanced Robert-
sonian translocation involving chromosome 21 or balanced reciprocal translocations) [18].
However, because of its low resolution, the need for cell cultivation, which is time-consuming
and artifact prone, and the inability to detect complex abnormalities, the chromosome analysis
is placed behind other high-throughput genomic investigations [19].
Currently, karyotyping remains the investigation of choice for low-risk pregnancies with
normal fetal morphology, like advanced maternal age with increased risk for trisomy 21 [22].
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3.2. Targeted molecular genetic testing
As mentioned above, about 10% of CAs is thought to be associated with monogenic disease
[4]. Ultrasound examination can detect many fetal structural abnormalities, from the early
anatomic survey in the first trimester to morphology and biometry in the second trimester
and monitoring of the fetal growth in the third trimester. In addition to ultrasound, fetal
magnetic resonance is now widely used to improve imaging of the central nervous system
structures [23].
The conventional genetic approach using targeted molecular methods, like Sanger or PCR, is
useful (enables) in the diagnostics of cases with ultrasonographically well-defined phenotypes
associated with specific diagnostic hypothesis in genetically homogenous CA (e.g., TAR,
achondroplasia) and is the method of choice for prenatal testing in cases of familial monogenic
condition with known pathogenic variant [24]. In cases with poorly defined phenotype and
genetically heterogeneous CAs (many genes responsible for the same phenotype), this
approach rarely warrants the diagnosis.
While the conventional genetic diagnostic approach is time-consuming, labor-intensive, and
with limited diagnostic yield, the new genomic approaches and technologies, like molecular
karyotyping and next-generation sequencing, offer new possibilities to establish specific pre-
natal genetic diagnosis in high-risk pregnancies.
3.3. Molecular karyotyping
Growing knowledge and important technical evolution in the last two decades enabled us, in
the clinical context, to detect and interpret smaller and smaller genomic imbalances. The
classical karyotyping has been replaced first by comparative genomic hybridization and soon
thereafter with array-based CGH (aCGH). It is becoming widely applied in the prenatal
setting, where it is recommended by many professional societies for routine prenatal diagnos-
tic testing in fetuses with ultrasound anomalies [25].
The comparative genomic hybridization using microarrays (aCGH) is based on competitive
hybridization of short segments of whole genome DNA to preprepared probes (short
sequences of DNA), spotted on a glass slide in a precise grid (microarray). The DNA of a
patient and reference sample DNA are both digested with restriction enzymes to generate
short fragments and after that labeled with two different fluorescent dyes. Both patient and
reference DNAs are combined and hybridized to the same microarray, thereby competing for
the same probes. A specialized scanner measures signal intensities and dedicated software
links signals to specific genomic regions (Figure 1). When there is a deletion in the patient, we
see it as a predominance of reference DNA in that genomic region. As a result, a relative log
ratio of patient’s signal compared to reference signal gives a curve with negative values.
Despite enabling the detection of progressively smaller genomic imbalances, one needs to be
aware of the limitations—the technique will not detect low-level mosaicism, triploidy, balanced
translocations, and point mutations.
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After performing several large prospective and retrospective studies, it is estimated that this
technique offers a 5–10% increase in detection of clinically relevant copy number variation in
fetuses with ultrasound anomalies (compared to conventional karyotyping) [3, 26–28].
In the first years, the technology has been used only in fetuses with multiple congenital
anomalies where the yield of pathogenic CNVs was reported to be up to 20%. With the broader
use, gained experience, and numerous data on normal variation, molecular karyotyping has
been introduced in different prenatal situations. It is also used in the cases of isolated congen-
ital anomalies, increased nuchal translucency only, or positive maternal serum screening. In
some countries, all prenatal genetic testing is performed with molecular karyotyping, if the
invasive approach has been employed [29]. Namely, a systematic review and meta-analysis of
17 evaluated studies demonstrated additional 5% of clinically relevant CNVs over conven-
tional karyotype in the group of fetuses with isolated increased nuchal translucency
NT > 3.5 mm. Even more, a copy number abnormality was identified in 1.7% of fetuses with a
normal ultrasonographic examination result with an indication for invasive testing being
advanced maternal age or positive aneuploidy screening test [28, 30].
Last but not least, molecular karyotyping has two additional benefits over classical karyotype.
As it does not need dividing cells, it can be performed directly from the prenatal sample,
Figure 1. Array CGH results in a prenatal case showing typical 22q11.2 deletion. The left side of the figure shows the
whole chromosome 22; the right side shows magnified region 22q11.
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speeding up the whole process and giving results in a few days. Even more, only a small
amount of DNA is needed, and therefore, it can be easily performed even on those samples
with an insufficient amount of material.
The abovementioned added diagnostic yield of microarrays over conventional karyotyping
provides evidence that molecular karyotyping should be used as a method of choice for the
analysis of potential genetic causes of fetal congenital anomalies. Consistent with this is the
ACOG committee opinion which states that molecular karyotyping is recommended instead of
a conventional karyotype when there is one or more ultrasonographically identified CAs in the
fetus [31].
However, there are still some limitations in prenatal settings, such as the possibility of
detecting variants of unknown significance (VOUS), CNV in susceptibility loci, and secondary
findings.
The identification of a variant of unknown significance (VOUS) still occurs in 0.3–1% of
prenatal cases, despite the wide use of the technology and diverse population data from pre-
and postnatal testing. The percentage depends on the resolution and type of the platform used
[28, 32]. Currently, there are no guidelines on how to deal with VOUS findings in the prenatal
settings. Different practices exist between laboratories. Parental samples can be obtained at the
same time as the prenatal sample, so that they are accessible if there is a need to test the origin
of certain VOUS identified in the fetus. On the other hand, they can be collected later in those
cases that need additional testing. The management of pregnancy is significantly influenced by
knowing if specific CNV is de novo or inherited. Some laboratories report all VOUS findings;
others only report such CNV when it occurs de novo and taking into account the size and
location of the identified CNV.
Yet again, different approaches can be employed when discussing detection and reporting of
secondary findings and CNV in susceptibility loci—some laboratories report all such findings,
whereas others have specific national or internal guidelines and lists of specific variants that
are reported and those that are not reported in prenatal settings [29, 33]. It is important to
emphasize the need for informative pretest genetic counseling, where these situations are
discussed with future parents.
Generally, it is well accepted that CNVs in susceptibility loci with higher penetrance are
reported as such in the context of prenatal genetic testing. A clear difference between such
findings and other known fully penetrant microdeletion/microduplication syndromes must be
presented to the pregnant couple.
3.4. Next-generation sequencing
Although microarray analysis has increased the diagnostic yield in comparison to conven-
tional karyotyping, a considerable proportion of fetuses with multiple CAs have a normal
karyotype and also a normal microarray result and thus remain without a definitive diagnosis.
Determining the cause of CAs in those cases is, during the prenatal period, usually very
challenging and frustrating. Genetic testing can be a long process, and the quick turnaround
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required for prenatal testing limits this process. Additionally, there is often an incomplete
presentation of characteristic phenotypes. So targeted gene sequencing is limited by poorly
defined phenotype, genetic heterogeneity, and a limited time period during pregnancy.
When CAs are associated with genetic changes in multiple genes, then sequencing the panel of
genes using next-generation sequencing (NGS) should be considered a method of choice. The
next-generation sequencing approach is based on parallel sequencing of multiple DNA frag-
ments in a single reaction. This enables high-throughput sequencing of large segments of
human genome in a cost-efficient manner (Figure 2).
While this approach is widely used in postnatal settings, its use is more limited prenatally, for
reasons similar to that of Sanger sequencing. The limitation of gene panel (gene targets)-based
approaches is in their dependence on correct diagnostic hypothesis and the long time to reach
a diagnosis in case appropriate panel is not selected or cannot be selected due to a nonspecific
clinical presentation. These issues can be addressed by using either mendeliome sequencing or
whole exome sequencing, which use NGS to sequence the coding exons of genes associated
with Mendelian diseases or all genes in the human genome, respectively. Mendeliome and
exome sequencing are achieved by capturing exonic sequences using exon-specific probes. In
Figure 2. Two causative variants are shown identified by next-generation sequencing (clinical exome sequencing) in a
fetus with Joubert syndrome. Part A depicts variant Cys615Arg and part B depicts variant Arg441Cys, both in TMEM67
gene. Both variants have previously been reported as pathogenic, and segregation analysis has shown them to be present
in the compound heterozygous form, clarifying the cause in this case.
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this way, exonic sequences of the human genome are enriched in the sample, making it
possible to focus sequencing on those regions. The principle benefit of this approach is that
rather than performing multiple separate gene panel tests for identification of monogenic
causes of CAs, a single genetic test is performed, and then results for any gene panel can be
inspected depending on the observed clinical signs and symptoms [34]. This makes such an
approach significantly faster and without the need for cascading numerous laboratory tests in
the case of negative results. Such an approach is also robust in cases with nonspecific clinical
presentation without a clear diagnostic hypothesis and in cases that were misdiagnosed.
Current reports have consistently shown the benefit of using exome sequencing in the diagno-
sis of fetal CA. The current evidence suggests that a genomic abnormality may be identified in
up to 20–30% of fetuses with multiple CA and with normal standard genetic results. While
initial reports have shown a modest added benefit of exome sequencing in multiple CAs [35],
later studies showed considerably higher yields. In a study by Drury et al., exome sequencing
could resolve additional 21% cases of pregnancies with multiple congenital anomalies, abnor-
mal ultrasound findings, and a normal microarray result [36]. Even higher diagnostic yields
were reported in more selected series of cases—a recent report has shown a positive yield of
47% in fetuses with high suspicion of an underlying genetic disorder and a negative microar-
ray and/or targeted tests [37]. Similarly, Alamillo and colleagues reported a relatively high
positive yield in patients with prenatal ultrasound anomalies [38]. These cases illustrate the
potentially important role of this new technology in the routine prenatal diagnostics of CAs.
Several studies have now shown that exome sequencing can also be used to detect structural
variants and a variety of other pathologic variants apart from simple single-nucleotide variants
[39]. This property makes exome sequencing an efficient test for structural and point variation.
Despite this, molecular karyotyping is still considered the method of choice in prenatal diag-
nostics, predominantly because of lower costs and well-established evidence of sensitivity and
specificity in the prenatal setting. With the reduction of the price of exome sequencing and
with increasing evidence supporting its sensitivity, we expect that next-generation sequencing
will ultimately be used for detection of structural and point mutations in a single test. Exome
sequencing is, however, a method of choice in multiple CAs cases with normal results of
molecular karyotyping and strong clinical suspicion of a monogenic etiology. Accordingly,
American College of Medical Genetics has released a policy statement suggesting that WES
can be used in the clinical assessment of “a fetus with a likely genetic disorder in which specific
genetic tests, including targeted sequencing tests, available for that phenotype have failed to
arrive at a diagnosis.” However, the statement stresses the limitations of the use of this
technology in the prenatal setting, including long turnaround times and high rates of false
positives, false negatives, and VOUS [40].
Despite several benefits outlined above, there are additional challenges associated with NGS-
based approaches, particularly in the prenatal diagnostic practice. Exome sequencing is a
demanding diagnostic test, requiring a complex set of laboratory, bioinformatic, and interpre-
tative steps before a clinical report may be issued. For this reason, its turnaround time usually
ranges from several weeks to several months. To address this issue, there is an incentive to
offer urgent exome sequencing service and thus offer provision of clinical reports within less
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than a month’s time. This significantly increases the utility of this test in prenatal diagnosis.
Sequencing of parental samples along with the fetal sample may also be used to facilitate the
timely interpretation of the sequencing results. Furthermore, we believe that limiting the set of
reported variants to known and clear pathogenicity is also an option in order to limit the
complexity of the analysis only to clinically actionable and conclusive results. Furthermore, as
in other genome-wide analysis approaches, NGS-based diagnostics inherently raise the issues
of incidental findings and variants of uncertain clinical significance. Due to limited time and
other specificities in prenatal diagnostics, several approaches should be employed to address
these issues. These include (1) limiting the gene target to genes with overlapping clinical
symptoms and signs and (2) limiting the reported variants to definitely pathogenic and likely
pathogenic variant classes. Furthermore, efficient collaboration within a multidisciplinary
team is often crucial in clarifying the clinical relevance of identified variants. Opting for this
approach, it is possible to utilize diagnostic advantages of NGS-based approaches while
reducing the chance of encountering uncertain and unsolicited findings. Nevertheless, exten-
sive genetic counseling should be offered to patients while stressing the possibility of identifi-
cation of VUS findings and incidental findings.
4. Proposed workflow
The goal of prenatal genetic testing in fetuses with CAs is to determine if there is a genetic
etiology and consequently enabling well-informed genetic counseling to the parents about the
prognosis, reproductive options, obstetric and pediatric management, and recurrence risks.
Different approaches of prenatal genetic diagnostics are used. Despite known evidence of
important additional diagnostic yield of new genomic technologies to the etiology of CAs,
most countries still use the traditional genetic diagnostic approach. Hereinafter we present a
diagnostic workflow that is currently in use at our institution (Figure 3). It incorporates the use
of new genomic technologies and is focused on the expected diagnostic yield and limited
diagnostic time frame.
When fetal CAs are detected on an ultrasound examination, we offer an invasive procedure for
diagnostic genetic testing.
In cases when specific chromosomal disorder (e.g., double bubble and trisomy 21) or mono-
genic syndrome is strongly suspected on the initial evaluation and single gene testing is
straightforward (e.g., achondroplasia), we exclude common aneuploidies (trisomy 13, 18, and
21, and aneuploidies of sex chromosomes) first, using quantitative fluorescence-polymerase
chain reaction (QF-PCR), and proceed with single gene testing, respectively.
When the specific clinical diagnosis is not apparent, we use a genomic approach for the
detection of genetic etiology of CAs. Because aneuploidies represent the commonest genetic
etiology of CAs, we first opt for QF-PCR to exclude the aneuploidies mentioned above.
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If the results are normal we proceed with molecular karyotyping instead of a conventional
karyotype as studies showed that this approach allows for the highest diagnostic yield. We use
this approach whether the anomaly appears to be isolated or multiple anomalies are detected.
In fetuses with normal results of molecular karyotyping, with multiple CAs, and a strong
clinical indication for monogenic etiology, we proceed with WES; our approach involves
sequencing the fetus as well as the biological parents (so-called trio sequencing), which
increases the diagnostic yield by filtering out thousands of uninformative genomic variants as
well as shortens the analysis turnaround time (less than 3 weeks at our institution).
In cases when CAs are lethal or have unfavorable prognosis, the parents often decide to
terminate the pregnancy, but for the purpose of genetic counseling, it is still important to
obtain the diagnosis. Accordingly, we shift the diagnostic process after the termination of the
pregnancy. Thorough dysmorphological and pathohistological evaluation may give additional
information on the specific phenotype and thus enables a more direct diagnostic approach in
the aborted fetus. Otherwise, we use the diagnostic approach similar to the approach during
the pregnancy.
Different medical specialists are involved in the process of prenatal diagnosis of CAs. The role of
a clinical geneticist in the whole pathway of genetic diagnostics of a pregnancy with CAs in a
close collaboration with other medical specialists (obstetricians, surgeons, radiologists, patholo-
gists, etc.) and amultidisciplinary approach is undisputed due to all the complexities of prenatal
diagnostics of CAs, their clinical presentation and phenotype evaluation, choice of the right
genetic testing strategies, interpretation of genetic testing results, and their communication
to patients and families.
Figure 3. Diagnostic algorithm for the prenatal genetic diagnostics of CAs. CAs, congenital anomalies; QF-PCR, quanti-
tative fluorescence-polymerase chain reaction; NGS, next-generation sequencing.
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5. Conclusions
With the advent of new genetic genomic technologies in the prenatal settings, the diagnostic
yield in the etiology of CAs can be significantly improved. This has important consequences
for the patients, as it enables the identification of the cause of CAs and, consequently, their
prevention, as well as understanding the genetic epidemiology of CAs and designing optimal
professional and cost-effective diagnostic algorithms for the diagnostics of CAs.
With the implementation of new genomic technologies in the diagnostic algorithm, approxi-
mately 50% of the genetic etiology of prenatally detected CAs can be explained. Therefore, we
suggest a timely implementation of these technologies in prenatal diagnostics of CAs.
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